Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Cancer
Conditions
Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Trial Timeline
May 25, 2020 → Jul 2, 2024
NCT ID
NCT04257448About Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule
Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule is a phase 1/2 stage product being developed by AstraZeneca for Pancreas Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04257448. Target conditions include Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04257448 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pancreas Cancer